Renerva Implants First PNM-CAP Device for Neuroma Pain
PITTSBURGH, May 13, 2026 Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PITTSBURGH, May 13, 2026 Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major...
NORTHBROOK, Ill., May 12, 2026 Astellas Pharma US announced new clinical findings showing that IZERVAY® (avacincaptad pegol intravitreal solution)...
